BIOMAT Database Logo BIOMAT Database Logo

Studies on the stability of VIII:C during the manufacture of a factor VIII concentrate for clinical use. 1988

P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
Scottish National Blood Transfusion Service, Protein Fractionation Centre, Edinburgh, UK.

The stability of VIII:C was investigated by monitoring samples taken at different points from a routine process for the manufacture of factor VIII concentrate and by examining the stabilising influence of a number of product formulations. Loss of VIII:C over process-finishing procedures (formulation, 0.22 micron filtration, dispensing) was associated with a citrate-induced inactivation which could be prevented by controlling the ionised calcium concentration of the solution. These results were obtained using a one-stage clotting assay but were not observed using a two-stage assay. No evidence for activation was found in vitro (e.g. by FPA generation and VIII:C stability) and the yield increase suggested by the one-stage assay was supported by results from a controlled clinical evaluation.

UI MeSH Term Description Entries
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002951 Citrates Derivatives of CITRIC ACID.
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D019343 Citric Acid A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability. Citrate,Anhydrous Citric Acid,Citric Acid Monohydrate,Citric Acid, Anhydrous,Uralyt U

Related Publications

P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
Studies on the stability of factor VIII coagulant antigen (VIII:CAg) in the presence of VIII:C antibodies.
January 1983, British journal of haematology,
P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
Concentrate of factor VIII (FI-O-Ta) for clinical use.
January 1968, Thrombosis et diathesis haemorrhagica. Supplementum,
P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
Use of frozen cryoprecipitate for the preparation of clinical factor VIII concentrate.
January 1973, Transfusion,
P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
[A new human factor VIII concentrate. Preparation and clinical use].
January 1981, Medicina,
P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
Immunologic studies of factor VIII coagulant activity (VIII:C). 2. Factor VIII in selected vertebrates.
March 1982, Thrombosis research,
P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
A new "high purity" factor VIII concentrate for clinical use in haemophilia.
June 1981, The Medical journal of Australia,
P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
May 1994, Journal of medical virology,
P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
Use of porcine Factor VIII concentrate.
January 1985, JAMA,
P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
January 1994, Vox sanguinis,
P R Foster, and I H Dickson, and T A McQuillan, and C V Prowse, and F E Boulton, and P Greedharry, and A L Bloom
Anti-A in factor VIII concentrate: a cause of severe hemolysis in a patient with acquired factor VIII:C antibodies.
June 1989, Infusionstherapie (Basel, Switzerland),
Copied contents to your clipboard!